At ESCMID 2025, early data suggest that Assembly Biosciences’ ABI-5366 could redefine the treatment landscape for recurrent genital herpes (RGH).

Sanofi will halt the development of its oral tumour necrosis factor (TNF) inhibitor balinatunfib as a monotherapy after it ...

Tiziana Life Sciences has announced the commencement of dosing in the fourth clinical site of the company’s Phase II trial of ...

The upcoming 12th Annual Clinical Trials in Oncology conference will cover a wide range of topics on clinical research in ...

Lokavant has launched the AI-powered clinical trial forecasting solution, Spectrum v15, to dispel uncertainty in the ...

After a number of Phase III successes in China, Summit is launching a multi-regional trial as the race for approval in the US and elsewhere across the globe begins. Image credit: Shutterstock / Tuhaa ...

EAGLE-1 trial data shows gepotidacin’s potential in treating gonorrhoea, for which no new antibiotics have been approved ...

According to the WHO, meningitis is a significant global health threat even though treatments and vaccines against some forms ...

Contraception for women has seen little change over the past 50 years, with the most prevalent contraceptive pills containing ...

Cellphire Therapeutics has stopped enrolling subjects in its CRYPTICS trial of CLPH-511 following feedback from an IDMC.

BMS has reported topline outcomes from the ARISE trial of Cobenfy as an adjunctive treatment to atypical antipsychotics for ...

Aclaris expects to begin the trial in the second quarter of the year. Credit: MacroEcon / Shutterstock. The US Food and Drug ...